Sun Pharmaceutical

Sun Pharma, headquartered in Mumbai, India, was established in 1983 by Dilip Shanghvi. It is the largest specialty generic pharmaceutical company in India, with a market share of over 8%, and the fourth largest in the world.

Sun Pharma offers a diverse range of products, including branded generics, generics, specialty products, over-the-counter products, and active pharmaceutical ingredients. It operates in more than 100 countries across six continents and has over 40 manufacturing facilities.

Sun Pharmaceutical Industries Limited reported financials for the fourth quarter & full year ending March 31st, 2022. In the fiscal year 2022, Sun Pharmaceutical Industries generated a consolidated income of over 39.500 scores Indian rupee. The company has a market capitalization of about $23 billion as of May 2023 and has consistently delivered profitable growth for its shareholders. Sun Pharma has also made significant investments in research and development to bring innovative solutions for unmet medical needs. With several milestones achieved, Sun Pharma has proven to be a reliable and professional player in the pharmaceutical industry.

Sun Pharma has achieved several milestones in its development over the recent years, such as launching a novel therapy for dry eye disease, showing positive results for osteoarthritis and alopecia areata candidates, acquiring Ranbaxy Laboratories and Taro Pharmaceutical Industries, and partnering with global players like Merck & Co., AstraZeneca, and Novartis.

Foundation: 1983
Headquarters: Mumbai, Maharashtra
Website: https://sunpharma.com/